We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers.
- Authors
Jantarabenjakul, Watsamon; Sodsai, Pimpayao; Chantasrisawad, Napaporn; Jitsatja, Anusara; Ninwattana, Sasiprapa; Thippamom, Nattakarn; Ruenjaiman, Vichaya; Tan, Chee Wah; Pradit, Rakchanok; Sophonphan, Jiratchaya; Wacharapluesadee, Supaporn; Wang, Lin-Fa; Puthanakit, Thanyawee; Hirankarn, Nattiya; Putcharoen, Opass
- Abstract
Inactivated SARS-CoV-2 vaccine (CoronaVac) is commonly used in national immunization programs. However, the immune response significantly declines within a few months. Our study assessed the immune response against SARS-CoV-2 after receiving booster shots of BNT162b2 or ChAdOx1 among health care workers who previously received CoronaVac as their primary immunization. Fifty-six participants who received ChAdOx1 and forty-two participants who received BNT162b2 were enrolled into this study, which evaluated immune responses, including anti-SARS-CoV-2 spike total antibodies (Elecsys®), surrogated viral neutralization test (sVNT) to ancestral strain (cPass™; GenScript), five variants of concern (Alpha, Beta, Gamma, Delta, and Omicron) (Luminex; multiplex sVNT) and the ELISpot with spike (S1 and S2) peptide pool against the ancestral SARS-CoV-2 strain. The samples were analyzed at baseline, 4, and 12 weeks after primary immunization, as well as 4 and 12 weeks after receiving the booster. This study showed a significant increase in anti-SARS-CoV-2 spike total antibodies, sVNT, and T-cell immune response after the booster, including against the Omicron variant. Immune responses rapidly decreased in the booster group at 12 weeks after booster but were still higher than post-primary vaccination. A fourth dose or a second booster should be recommended, particularly in health care workers.
- Subjects
MEDICAL personnel; SARS-CoV-2; COVID-19 vaccines; BOOSTER vaccines; ANTIBODY formation
- Publication
Vaccines, 2022, Vol 10, Issue 5, p639
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines10050639